This page lists the SEC filings reported by RA Capital Management.
| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13G | 2023-10-05 | RA CAPITAL MANAGEMENT, L.P. | SOLENO THERAPEUTICS INC | 1,233,300 | 4.6% | EDGAR |
| SC 13G | 2023-09-29 | RA CAPITAL MANAGEMENT, L.P. | CHIMERIX INC | 6,501,624 | 7.3% | EDGAR |
| SC 13D/A | 2023-09-25 | RA CAPITAL MANAGEMENT, L.P. | ARS Pharmaceuticals, Inc. | 9,459,678 | 9.9% | EDGAR |
| SC 13G | 2023-09-22 | RA CAPITAL MANAGEMENT, L.P. | CymaBay Therapeutics, Inc. | 6,940,000 | 6.2% | EDGAR |
| SC 13D/A | 2023-09-19 | RA CAPITAL MANAGEMENT, L.P. | Cytek Biosciences, Inc. | 6,809,404 | 5.0% | EDGAR |
| SC 13D | 2023-08-31 | RA CAPITAL MANAGEMENT, L.P. | ARS Pharmaceuticals, Inc. | 6,759,678 | 7.1% | EDGAR |
| SC 13G | 2023-08-25 | RA CAPITAL MANAGEMENT, L.P. | Taysha Gene Therapies, Inc. | 18,690,868 | 10.0% | EDGAR |
| SC 13G | 2023-08-21 | RA CAPITAL MANAGEMENT, L.P. | Gracell Biotechnologies Inc. | 48,600,300 | 10.0% | EDGAR |
| SC 13G | 2023-08-17 | RA CAPITAL MANAGEMENT, L.P. | NEKTAR THERAPEUTICS | 18,700,000 | 9.8% | EDGAR |
| SC 13G/A | 2023-08-14 | RA CAPITAL MANAGEMENT, L.P. | Kinnate Biopharma Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2023-08-14 | RA CAPITAL MANAGEMENT, L.P. | BELLUS Health Inc. | 0 | 0.0% | EDGAR |
| SC 13D/A | 2023-08-11 | RA CAPITAL MANAGEMENT, L.P. | 89bio, Inc. | 12,874,814 | 16.7% | EDGAR |
| SC 13D/A | 2023-08-11 | RA CAPITAL MANAGEMENT, L.P. | Vor Biopharma Inc. | 22,780,343 | 33.7% | EDGAR |
| SC 13D/A | 2023-08-09 | RA CAPITAL MANAGEMENT, L.P. | DICE Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2023-08-01 | RA CAPITAL MANAGEMENT, L.P. | NewAmsterdam Pharma Co N.V. | 9,333,333 | 11.3% | EDGAR |
| SC 13D/A | 2023-07-25 | RA CAPITAL MANAGEMENT, L.P. | Acumen Pharmaceuticals, Inc. | 14,981,618 | 25.9% | EDGAR |
| SC 13G | 2023-07-06 | RA CAPITAL MANAGEMENT, L.P. | Unicycive Therapeutics, Inc. | 3,470,689 | 10.0% | EDGAR |
| SC 13G | 2023-07-06 | RA CAPITAL MANAGEMENT, L.P. | Talaris Therapeutics, Inc. | 2,333,175 | 5.5% | EDGAR |
| SC 13D/A | 2023-06-27 | RA CAPITAL MANAGEMENT, L.P. | Aerovate Therapeutics, Inc. | 8,293,148 | 30.0% | EDGAR |
| SC 13D/A | 2023-06-21 | RA CAPITAL MANAGEMENT, L.P. | DICE Therapeutics, Inc. | 7,877,862 | 16.5% | EDGAR |
- Form 13F-HR
- The 13F-HR report is filed quarterly to report securities held by the filer that fall under the SEC's 13F rules.
- Form SC 13D/G
- Reported by persons and groups who own 5% or more of any class of a company's outstanding shares. If the ownership changes by 1% or more, an amendment must be filed.
- Form 3, 4, and 5
- Form 3, 4, and 5 reports are filed to report insider transactions by company officers and directors, and any beneficial owners of more than ten percent of a company's shares. Form 3 is the initial report that must be filed when a person becomes an officer, director, or beneficial owner. Form 4 reports are used to report changes in ownership, while the Form 5 report is used for reporting transactions that should have been reported earlier in a Form 4 filing.